[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXV0pRTxQG248qA3tCfaz5_s03m-xqjznpaWHm7915Wk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":61,"rows":68},"Guy's and St Thomas' NHS Foundation Trust",[4],286,false,57,16,106553,9,248,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Heart Failure",12,{"name":18,"count":19},"COPD",8,{"name":21,"count":22},"Cataract",7,{"name":24,"count":22},"Prostate Cancer",{"name":26,"count":27},"Critical Illness",6,{"name":29,"count":27},"Asthma",{"name":31,"count":27},"Chronic Obstructive Pulmonary Disease",{"name":33,"count":34},"Acute Kidney Injury",5,[36,41,46,51,56],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04806061","Urine Alkalinisation in COVID-19","2024-07-30","Sodium bicarbonate",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06731881","Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections","2025-08-31","Photosensitizer formulation only",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07169513","Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis","2026-07-01","Aspirin 75 mg daily",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05434104","The LISA (Lactoferrin InStead of Antibiotics\u002FAntifungals) Feasibility Study","2027-12","Usual care",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06347536","Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease","2027-12-31","Supported rescue pack",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,93,119,137,155,173,195,218,236,259,285,315,333,351,369,387,414,432,458,476,501,529,547,574,592,618,636,660,684,711,737,755,784,811,829,856,874,898,927,945,973,991,1018,1044,1062,1097,1125,1151,1176,1199,1222,1248,1266,1291,1309,1336,1363,1381,1409],{"intervention":60,"totalTrials":70,"cells":71},1,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":89,"NA":91},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":74},[],{"trials":80,"activeCount":70,"soonestReadout":59},[81],{"nctId":57,"briefTitle":58,"status":82,"phases":83,"primaryCompletion":59,"completion":59,"start":84,"enrollment":85,"conditions":86,"interventions":88},"RECRUITING",[65],"2025-01-30",1400,[18,87],"COPD Exacerbation",[60],{"trials":90,"activeCount":74},[],{"trials":92,"activeCount":74},[],{"intervention":50,"totalTrials":70,"cells":94},{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":105},{"trials":96,"activeCount":74},[],{"trials":98,"activeCount":74},[],{"trials":100,"activeCount":74},[],{"trials":102,"activeCount":74},[],{"trials":104,"activeCount":74},[],{"trials":106,"activeCount":70,"soonestReadout":49},[107],{"nctId":47,"briefTitle":48,"status":108,"phases":109,"primaryCompletion":49,"completion":49,"start":110,"enrollment":111,"conditions":112,"interventions":115},"NOT_YET_RECRUITING",[67],"2025-10-01",60,[113,114],"Peripheral Arterial Disease","Silent Atherosclerosis",[50,116,117,118],"Clopidogrel 75 mg daily","Clopidgrel 75 mg daily","Aspirin 75 mg daily + Clopidgrel 75 mg daily",{"intervention":116,"totalTrials":70,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":131},{"trials":122,"activeCount":74},[],{"trials":124,"activeCount":74},[],{"trials":126,"activeCount":74},[],{"trials":128,"activeCount":74},[],{"trials":130,"activeCount":74},[],{"trials":132,"activeCount":70,"soonestReadout":49},[133],{"nctId":47,"briefTitle":48,"status":108,"phases":134,"primaryCompletion":49,"completion":49,"start":110,"enrollment":111,"conditions":135,"interventions":136},[67],[113,114],[50,116,117,118],{"intervention":117,"totalTrials":70,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":140,"activeCount":74},[],{"trials":142,"activeCount":74},[],{"trials":144,"activeCount":74},[],{"trials":146,"activeCount":74},[],{"trials":148,"activeCount":74},[],{"trials":150,"activeCount":70,"soonestReadout":49},[151],{"nctId":47,"briefTitle":48,"status":108,"phases":152,"primaryCompletion":49,"completion":49,"start":110,"enrollment":111,"conditions":153,"interventions":154},[67],[113,114],[50,116,117,118],{"intervention":118,"totalTrials":70,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":167},{"trials":158,"activeCount":74},[],{"trials":160,"activeCount":74},[],{"trials":162,"activeCount":74},[],{"trials":164,"activeCount":74},[],{"trials":166,"activeCount":74},[],{"trials":168,"activeCount":70,"soonestReadout":49},[169],{"nctId":47,"briefTitle":48,"status":108,"phases":170,"primaryCompletion":49,"completion":49,"start":110,"enrollment":111,"conditions":171,"interventions":172},[67],[113,114],[50,116,117,118],{"intervention":55,"totalTrials":70,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":185},{"trials":176,"activeCount":74},[],{"trials":178,"activeCount":74},[],{"trials":180,"activeCount":74},[],{"trials":182,"activeCount":74},[],{"trials":184,"activeCount":74},[],{"trials":186,"activeCount":70,"soonestReadout":54},[187],{"nctId":52,"briefTitle":53,"status":82,"phases":188,"primaryCompletion":54,"completion":54,"start":189,"enrollment":190,"conditions":191,"interventions":194},[67],"2026-04-16",114,[192,193],"Bacterial Vaginosis","Candida Vaginal",[55],{"intervention":40,"totalTrials":70,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":198,"activeCount":74},[],{"trials":200,"activeCount":74},[],{"trials":202,"activeCount":74},[],{"trials":204,"activeCount":74},[],{"trials":206,"activeCount":74},[],{"trials":208,"activeCount":70,"soonestReadout":39},[209],{"nctId":37,"briefTitle":38,"status":210,"phases":211,"primaryCompletion":39,"completion":39,"start":212,"enrollment":213,"conditions":214,"interventions":216},"ACTIVE_NOT_RECRUITING",[67],"2021-10-15",80,[215,33],"Covid19",[40,217],"standard care",{"intervention":217,"totalTrials":70,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":230},{"trials":221,"activeCount":74},[],{"trials":223,"activeCount":74},[],{"trials":225,"activeCount":74},[],{"trials":227,"activeCount":74},[],{"trials":229,"activeCount":74},[],{"trials":231,"activeCount":70,"soonestReadout":39},[232],{"nctId":37,"briefTitle":38,"status":210,"phases":233,"primaryCompletion":39,"completion":39,"start":212,"enrollment":213,"conditions":234,"interventions":235},[67],[215,33],[40,217],{"intervention":45,"totalTrials":70,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":239,"activeCount":74},[],{"trials":241,"activeCount":74},[],{"trials":243,"activeCount":74},[],{"trials":245,"activeCount":74},[],{"trials":247,"activeCount":74},[],{"trials":249,"activeCount":70,"soonestReadout":44},[250],{"nctId":42,"briefTitle":43,"status":82,"phases":251,"primaryCompletion":44,"completion":252,"start":253,"enrollment":213,"conditions":254,"interventions":258},[67],"2025-10-31","2025-06-04",[255,256,257],"Surgery","Nasal Disease","Light; Therapy, Complications",[45],{"intervention":260,"totalTrials":70,"cells":261},"Vedolizumab",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":283},{"trials":263,"activeCount":74},[],{"trials":265,"activeCount":74},[],{"trials":267,"activeCount":74},[],{"trials":269,"activeCount":74},[],{"trials":271,"activeCount":74},[272],{"nctId":273,"briefTitle":274,"status":275,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT04006080","Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis","UNKNOWN",[66],"2020-03","2019-07-01",30,[281],"Ulcerative Colitis",[260],{"trials":284,"activeCount":74},[],{"intervention":286,"totalTrials":70,"cells":287},"Rituximab",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":313},{"trials":289,"activeCount":74},[],{"trials":291,"activeCount":74},[],{"trials":293,"activeCount":74},[],{"trials":295,"activeCount":74},[],{"trials":297,"activeCount":74},[298],{"nctId":299,"briefTitle":300,"status":275,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT01095172","RituxiMab INDuction in Renal Transplantation",[66],"2020-10","2022-10","2010-11",100,[307],"Function of Renal Transplant",[286,309,310,311,312,312],"Tacrolimus","Mycophenylate mofetil","Hydrocortisone","Prednisolone",{"trials":314,"activeCount":74},[],{"intervention":309,"totalTrials":70,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":331},{"trials":318,"activeCount":74},[],{"trials":320,"activeCount":74},[],{"trials":322,"activeCount":74},[],{"trials":324,"activeCount":74},[],{"trials":326,"activeCount":74},[327],{"nctId":299,"briefTitle":300,"status":275,"phases":328,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":329,"interventions":330},[66],[307],[286,309,310,311,312,312],{"trials":332,"activeCount":74},[],{"intervention":310,"totalTrials":70,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":349},{"trials":336,"activeCount":74},[],{"trials":338,"activeCount":74},[],{"trials":340,"activeCount":74},[],{"trials":342,"activeCount":74},[],{"trials":344,"activeCount":74},[345],{"nctId":299,"briefTitle":300,"status":275,"phases":346,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":347,"interventions":348},[66],[307],[286,309,310,311,312,312],{"trials":350,"activeCount":74},[],{"intervention":311,"totalTrials":70,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":367},{"trials":354,"activeCount":74},[],{"trials":356,"activeCount":74},[],{"trials":358,"activeCount":74},[],{"trials":360,"activeCount":74},[],{"trials":362,"activeCount":74},[363],{"nctId":299,"briefTitle":300,"status":275,"phases":364,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":365,"interventions":366},[66],[307],[286,309,310,311,312,312],{"trials":368,"activeCount":74},[],{"intervention":312,"totalTrials":70,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":385},{"trials":372,"activeCount":74},[],{"trials":374,"activeCount":74},[],{"trials":376,"activeCount":74},[],{"trials":378,"activeCount":74},[],{"trials":380,"activeCount":74},[381],{"nctId":299,"briefTitle":300,"status":275,"phases":382,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":383,"interventions":384},[66],[307],[286,309,310,311,312,312],{"trials":386,"activeCount":74},[],{"intervention":388,"totalTrials":70,"cells":389},"Maraviroc",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":412},{"trials":391,"activeCount":74},[],{"trials":393,"activeCount":74},[],{"trials":395,"activeCount":74},[],{"trials":397,"activeCount":74},[],{"trials":399,"activeCount":74},[400],{"nctId":401,"briefTitle":402,"status":403,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT04965662","The Role of Home Packs of HIV PEPSE in High Risk Individuals","COMPLETED",[66],"2021-03-16","2018-01-01",139,[409],"HIV-1-infection",[388,411],"Truvada",{"trials":413,"activeCount":74},[],{"intervention":411,"totalTrials":70,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":424,"NA":430},{"trials":417,"activeCount":74},[],{"trials":419,"activeCount":74},[],{"trials":421,"activeCount":74},[],{"trials":423,"activeCount":74},[],{"trials":425,"activeCount":74},[426],{"nctId":401,"briefTitle":402,"status":403,"phases":427,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":428,"interventions":429},[66],[409],[388,411],{"trials":431,"activeCount":74},[],{"intervention":433,"totalTrials":70,"cells":434},"Co-Amoxiclav",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":456},{"trials":436,"activeCount":74},[],{"trials":438,"activeCount":74},[],{"trials":440,"activeCount":74},[],{"trials":442,"activeCount":74},[],{"trials":444,"activeCount":74},[445],{"nctId":446,"briefTitle":447,"status":403,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT02089568","Prophylaxis Of Wound Infections- Antibiotics in Renal Donation",[66],"2016-08","2012-07",284,[453],"Infection",[433,455],"Normal Saline",{"trials":457,"activeCount":74},[],{"intervention":455,"totalTrials":70,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":474},{"trials":461,"activeCount":74},[],{"trials":463,"activeCount":74},[],{"trials":465,"activeCount":74},[],{"trials":467,"activeCount":74},[],{"trials":469,"activeCount":74},[470],{"nctId":446,"briefTitle":447,"status":403,"phases":471,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":472,"interventions":473},[66],[453],[433,455],{"trials":475,"activeCount":74},[],{"intervention":477,"totalTrials":70,"cells":478},"Prevenar 13",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":499},{"trials":480,"activeCount":74},[],{"trials":482,"activeCount":74},[],{"trials":484,"activeCount":74},[],{"trials":486,"activeCount":74},[],{"trials":488,"activeCount":74},[489],{"nctId":490,"briefTitle":491,"status":403,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT03565159","Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors",[66],"2023-08-31","2018-08-02",214,[497],"Sepsis",[477],{"trials":500,"activeCount":74},[],{"intervention":502,"totalTrials":70,"cells":503},"Mycophenolate mofetil",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":527},{"trials":505,"activeCount":74},[],{"trials":507,"activeCount":74},[],{"trials":509,"activeCount":74},[],{"trials":511,"activeCount":74},[],{"trials":513,"activeCount":74},[514],{"nctId":515,"briefTitle":516,"status":403,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":525},"NCT01101802","Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)",[66],"2008-03","2008-10","2006-03",71,[523,524],"Systemic Lupus Erythematosus","Atherosclerosis",[502,526],"sugar pill",{"trials":528,"activeCount":74},[],{"intervention":526,"totalTrials":70,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":74},[],{"trials":534,"activeCount":74},[],{"trials":536,"activeCount":74},[],{"trials":538,"activeCount":74},[],{"trials":540,"activeCount":74},[541],{"nctId":515,"briefTitle":516,"status":403,"phases":542,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":543,"interventions":544},[66],[523,524],[502,526],{"trials":546,"activeCount":74},[],{"intervention":548,"totalTrials":70,"cells":549},"0.5% levobupivacaine",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":572},{"trials":551,"activeCount":74},[],{"trials":553,"activeCount":74},[],{"trials":555,"activeCount":74},[],{"trials":557,"activeCount":74},[],{"trials":559,"activeCount":74},[560],{"nctId":561,"briefTitle":562,"status":563,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":74,"conditions":568,"interventions":570},"NCT01160965","Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural","WITHDRAWN",[66],"2013-08","2014-08","2012-08",[569],"Caesarean Section",[548,571],"0.75% Ropivacaine",{"trials":573,"activeCount":74},[],{"intervention":571,"totalTrials":70,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":590},{"trials":577,"activeCount":74},[],{"trials":579,"activeCount":74},[],{"trials":581,"activeCount":74},[],{"trials":583,"activeCount":74},[],{"trials":585,"activeCount":74},[586],{"nctId":561,"briefTitle":562,"status":563,"phases":587,"primaryCompletion":565,"completion":566,"start":567,"enrollment":74,"conditions":588,"interventions":589},[66],[569],[548,571],{"trials":591,"activeCount":74},[],{"intervention":593,"totalTrials":70,"cells":594},"Prilocaine",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":616},{"trials":596,"activeCount":74},[],{"trials":598,"activeCount":74},[],{"trials":600,"activeCount":74},[],{"trials":602,"activeCount":74},[],{"trials":604,"activeCount":74},[605],{"nctId":606,"briefTitle":607,"status":275,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":614},"NCT04394533","Hyperbaric Prilocaine Compared With Hyperbaric Bupivacaine in Cervical Cerclage?",[66],"2024-08-31","2021-08-27",135,[613],"Cervical Incompetence in Pregnancy as Antepartum Condition",[593,615],"Bupivacaine",{"trials":617,"activeCount":74},[],{"intervention":615,"totalTrials":70,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":634},{"trials":621,"activeCount":74},[],{"trials":623,"activeCount":74},[],{"trials":625,"activeCount":74},[],{"trials":627,"activeCount":74},[],{"trials":629,"activeCount":74},[630],{"nctId":606,"briefTitle":607,"status":275,"phases":631,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":632,"interventions":633},[66],[613],[593,615],{"trials":635,"activeCount":74},[],{"intervention":637,"totalTrials":70,"cells":638},"Golimumab",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":658},{"trials":640,"activeCount":74},[],{"trials":642,"activeCount":74},[],{"trials":644,"activeCount":74},[],{"trials":646,"activeCount":74},[],{"trials":648,"activeCount":74},[649],{"nctId":650,"briefTitle":651,"status":403,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":657},"NCT03124121","Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels",[66],"2019-09-30","2017-09-05",112,[281],[637],{"trials":659,"activeCount":74},[],{"intervention":661,"totalTrials":70,"cells":662},"Metformin",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":682},{"trials":664,"activeCount":74},[],{"trials":666,"activeCount":74},[],{"trials":668,"activeCount":74},[],{"trials":670,"activeCount":74},[],{"trials":672,"activeCount":74},[673],{"nctId":674,"briefTitle":675,"status":275,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT02511665","Metformin And Longevity",[66],"2017-07","2015-07",185,[24],[661],{"trials":683,"activeCount":74},[],{"intervention":685,"totalTrials":70,"cells":686},"Xolair",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":709},{"trials":688,"activeCount":74},[],{"trials":690,"activeCount":74},[],{"trials":692,"activeCount":74},[],{"trials":694,"activeCount":74},[],{"trials":696,"activeCount":74},[697],{"nctId":698,"briefTitle":699,"status":403,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":708},"NCT02300701","Role of Anti-IgE in Severe Childhood Eczema",[66],"2018-08","2014-12",62,[705,706,707],"Atopic Eczema","Atopic Dermatitis","Child",[685],{"trials":710,"activeCount":74},[],{"intervention":712,"totalTrials":70,"cells":713},"Raltegravir 400Mg Tab",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":735},{"trials":715,"activeCount":74},[],{"trials":717,"activeCount":74},[],{"trials":719,"activeCount":74},[],{"trials":721,"activeCount":74},[],{"trials":723,"activeCount":74},[724],{"nctId":725,"briefTitle":726,"status":403,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":733},"NCT03205566","Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection",[66],"2018-09-24","2017-09-19",38,[732],"Hiv",[712,734],"Lamivudine 150Mg",{"trials":736,"activeCount":74},[],{"intervention":734,"totalTrials":70,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":753},{"trials":740,"activeCount":74},[],{"trials":742,"activeCount":74},[],{"trials":744,"activeCount":74},[],{"trials":746,"activeCount":74},[],{"trials":748,"activeCount":74},[749],{"nctId":725,"briefTitle":726,"status":403,"phases":750,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":751,"interventions":752},[66],[732],[712,734],{"trials":754,"activeCount":74},[],{"intervention":756,"totalTrials":70,"cells":757},"Hydroxychloroquine",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":782},{"trials":759,"activeCount":74},[],{"trials":761,"activeCount":74},[],{"trials":763,"activeCount":74},[],{"trials":765,"activeCount":74},[],{"trials":767,"activeCount":74},[768],{"nctId":769,"briefTitle":770,"status":771,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":781},"NCT04316494","Hydroxychloroquine in ANCA Vasculitis Evaluation","TERMINATED",[66],"2025-05-15","2020-12-17",43,[777,778,779,780],"ANCA Associated Vasculitis","Microscopic Polyangiitis","Churg-Strauss Syndrome","Wegener Granulomatosis",[756],{"trials":783,"activeCount":74},[],{"intervention":785,"totalTrials":70,"cells":786},"Intravenous Methylprednisolone",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":807,"NA":809},{"trials":788,"activeCount":74},[],{"trials":790,"activeCount":74},[],{"trials":792,"activeCount":74},[],{"trials":794,"activeCount":74},[795],{"nctId":796,"briefTitle":797,"status":771,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":805},"NCT02398994","A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis",[65],"2016-03","2015-03",2,[803,804],"Myelitis, Transverse","Neuromyelitis Optica",[785,806],"Intravenous Immunoglobulin",{"trials":808,"activeCount":74},[],{"trials":810,"activeCount":74},[],{"intervention":806,"totalTrials":70,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":825,"NA":827},{"trials":814,"activeCount":74},[],{"trials":816,"activeCount":74},[],{"trials":818,"activeCount":74},[],{"trials":820,"activeCount":74},[821],{"nctId":796,"briefTitle":797,"status":771,"phases":822,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":823,"interventions":824},[65],[803,804],[785,806],{"trials":826,"activeCount":74},[],{"trials":828,"activeCount":74},[],{"intervention":830,"totalTrials":70,"cells":831},"Remimazolam",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":852,"NA":854},{"trials":833,"activeCount":74},[],{"trials":835,"activeCount":74},[],{"trials":837,"activeCount":74},[],{"trials":839,"activeCount":74},[840],{"nctId":841,"briefTitle":842,"status":275,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT05220462","Remimazolam vs Midazolam Cognitive and Motor Recovery After Intravenous Conscious Sedation for Dental Extractions.",[65],"2024-05-01","2024-09-01","2022-03-09",128,[849],"Tooth Extraction",[830,851],"Midazolam",{"trials":853,"activeCount":74},[],{"trials":855,"activeCount":74},[],{"intervention":851,"totalTrials":70,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":870,"NA":872},{"trials":859,"activeCount":74},[],{"trials":861,"activeCount":74},[],{"trials":863,"activeCount":74},[],{"trials":865,"activeCount":74},[866],{"nctId":841,"briefTitle":842,"status":275,"phases":867,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":868,"interventions":869},[65],[849],[830,851],{"trials":871,"activeCount":74},[],{"trials":873,"activeCount":74},[],{"intervention":875,"totalTrials":70,"cells":876},"Sodium Bicarbonate 150Meq\u002FL\u002FD5W Inj",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":894,"NA":896},{"trials":878,"activeCount":74},[],{"trials":880,"activeCount":74},[],{"trials":882,"activeCount":74},[],{"trials":884,"activeCount":74},[885],{"nctId":886,"briefTitle":887,"status":275,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":213,"conditions":892,"interventions":893},"NCT04655716","Urine Alkalinisation to Prevent AKI in COVID-19",[65],"2022-06-30","2022-12-31","2021-07-19",[215],[875],{"trials":895,"activeCount":74},[],{"trials":897,"activeCount":74},[],{"intervention":899,"totalTrials":70,"cells":900},"Propofol",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":923,"NA":925},{"trials":902,"activeCount":74},[],{"trials":904,"activeCount":74},[],{"trials":906,"activeCount":74},[],{"trials":908,"activeCount":74},[909],{"nctId":910,"briefTitle":911,"status":275,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":921},"NCT06014138","Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome",[64,65],"2024-12-31","2025-03-31","2023-11-01",20,[918,919,920],"Acute Respiratory Distress Syndrome","Mechanical Ventilation Complication","Sedation Complication",[899,922],"Isoflurane",{"trials":924,"activeCount":74},[],{"trials":926,"activeCount":74},[],{"intervention":922,"totalTrials":70,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":941,"NA":943},{"trials":930,"activeCount":74},[],{"trials":932,"activeCount":74},[],{"trials":934,"activeCount":74},[],{"trials":936,"activeCount":74},[937],{"nctId":910,"briefTitle":911,"status":275,"phases":938,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":939,"interventions":940},[64,65],[918,919,920],[899,922],{"trials":942,"activeCount":74},[],{"trials":944,"activeCount":74},[],{"intervention":946,"totalTrials":70,"cells":947},"Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL",{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":969,"NA":971},{"trials":949,"activeCount":74},[],{"trials":951,"activeCount":74},[],{"trials":953,"activeCount":74},[],{"trials":955,"activeCount":74},[956],{"nctId":957,"briefTitle":958,"status":275,"phases":959,"primaryCompletion":960,"completion":913,"start":961,"enrollment":305,"conditions":962,"interventions":967},"NCT04209868","Preoperative Paravertebral Block in Cancer Surgery of the Lung",[64,65],"2024-12","2019-02-01",[963,964,965,966],"Thoracic Neoplasm","Chronic Pain Post-Procedural","Acute Post-thoracotomy Pain","Anesthesia, Local",[946,968],"0.9% Sodium Chloride 20mL",{"trials":970,"activeCount":74},[],{"trials":972,"activeCount":74},[],{"intervention":968,"totalTrials":70,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":987,"NA":989},{"trials":976,"activeCount":74},[],{"trials":978,"activeCount":74},[],{"trials":980,"activeCount":74},[],{"trials":982,"activeCount":74},[983],{"nctId":957,"briefTitle":958,"status":275,"phases":984,"primaryCompletion":960,"completion":913,"start":961,"enrollment":305,"conditions":985,"interventions":986},[64,65],[963,964,965,966],[946,968],{"trials":988,"activeCount":74},[],{"trials":990,"activeCount":74},[],{"intervention":992,"totalTrials":70,"cells":993},"botulinum toxin intramuscular",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1014,"NA":1016},{"trials":995,"activeCount":74},[],{"trials":997,"activeCount":74},[],{"trials":999,"activeCount":74},[],{"trials":1001,"activeCount":74},[1002],{"nctId":1003,"briefTitle":1004,"status":403,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1013},"NCT01437644","The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial",[65],"2014-09","2015-01","2011-10",54,[1011,1012],"Cerebral Palsy","Post-operative Pain",[992],{"trials":1015,"activeCount":74},[],{"trials":1017,"activeCount":74},[],{"intervention":1019,"totalTrials":70,"cells":1020},"Phylloquinone",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1040,"NA":1042},{"trials":1022,"activeCount":74},[],{"trials":1024,"activeCount":74},[],{"trials":1026,"activeCount":74},[],{"trials":1028,"activeCount":74},[1029],{"nctId":1030,"briefTitle":1031,"status":275,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1038},"NCT01232647","Vitamin K as Additive Treatment in Osteoporosis",[64,65],"2020-03-31","2015-04",105,[1037],"Post-menopausal Osteoporosis",[1019,1039],"Menatetrenone",{"trials":1041,"activeCount":74},[],{"trials":1043,"activeCount":74},[],{"intervention":1039,"totalTrials":70,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1058,"NA":1060},{"trials":1047,"activeCount":74},[],{"trials":1049,"activeCount":74},[],{"trials":1051,"activeCount":74},[],{"trials":1053,"activeCount":74},[1054],{"nctId":1030,"briefTitle":1031,"status":275,"phases":1055,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":1035,"conditions":1056,"interventions":1057},[64,65],[1037],[1019,1039],{"trials":1059,"activeCount":74},[],{"trials":1061,"activeCount":74},[],{"intervention":1063,"totalTrials":801,"cells":1064},"Autologous regulatory T Cell Product",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1066,"activeCount":74},[],{"trials":1068,"activeCount":74},[],{"trials":1070,"activeCount":74},[1071,1081],{"nctId":1072,"briefTitle":1073,"status":403,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1080},"NCT02129881","The ONE Study UK Treg Trial",[63,64],"2017-03-23","2014-04",15,[1079],"End-stage Renal Failure",[1063],{"nctId":1082,"briefTitle":1083,"status":403,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":11,"conditions":1087,"interventions":1089},"NCT02166177","Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients",[63,64],"2018-01-22","2014-06",[1088],"End-stage Liver Disease",[1090],"Autologous regulatory T cell product",{"trials":1092,"activeCount":74},[],{"trials":1094,"activeCount":74},[],{"trials":1096,"activeCount":74},[],{"intervention":1098,"totalTrials":70,"cells":1099},"Serial prophylactic exchange blood transfusion (SPEBT).",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1101,"activeCount":74},[],{"trials":1103,"activeCount":74},[],{"trials":1105,"activeCount":74},[1106],{"nctId":1107,"briefTitle":1108,"status":275,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1118},"NCT03975894","TAPS2 Transfusion Antenatally in Pregnant Women With SCD",[64],"2020-12-01","2021-05-01","2019-05-02",50,[1115,1116,1117],"Sickle Cell Disease","Pregnancy, High Risk","Blood Transfusion Complication",[1098],{"trials":1120,"activeCount":74},[],{"trials":1122,"activeCount":74},[],{"trials":1124,"activeCount":74},[],{"intervention":1126,"totalTrials":70,"cells":1127},"MON002",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1129,"activeCount":74},[],{"trials":1131,"activeCount":74},[],{"trials":1133,"activeCount":74},[1134],{"nctId":1135,"briefTitle":1136,"status":275,"phases":1137,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":34,"conditions":1141,"interventions":1144},"NCT04805086","The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19",[63,64],"2022-06-01","2023-03-05","2021-03-08",[1142,1143,215],"Pulmonary Fibrosis","Interstitial Lung Disease",[1126],{"trials":1146,"activeCount":74},[],{"trials":1148,"activeCount":74},[],{"trials":1150,"activeCount":74},[],{"intervention":1152,"totalTrials":70,"cells":1153},"AEONTM Repair and AEONTM Protect Plus lubricating eye drops",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1155,"activeCount":74},[],{"trials":1157,"activeCount":74},[],{"trials":1159,"activeCount":74},[],{"trials":1161,"activeCount":74},[],{"trials":1163,"activeCount":74},[],{"trials":1165,"activeCount":74},[1166],{"nctId":1167,"briefTitle":1168,"status":403,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT04465071","Lubricating Eye Drops After Routine Cataract Surgery",[67],"2022-08-31","2020-02-24",79,[1174,21],"Dry Eye",[1152],{"intervention":1177,"totalTrials":70,"cells":1178},"Benralizumab",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1180,"activeCount":74},[],{"trials":1182,"activeCount":74},[],{"trials":1184,"activeCount":74},[],{"trials":1186,"activeCount":74},[],{"trials":1188,"activeCount":74},[],{"trials":1190,"activeCount":74},[1191],{"nctId":1192,"briefTitle":1193,"status":275,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":16,"conditions":1197,"interventions":1198},"NCT05847452","Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI)",[],"2025-01","2023-05-22",[29],[1177],{"intervention":1200,"totalTrials":70,"cells":1201},"mitomycin-C",{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1203,"activeCount":74},[],{"trials":1205,"activeCount":74},[],{"trials":1207,"activeCount":74},[],{"trials":1209,"activeCount":74},[],{"trials":1211,"activeCount":74},[],{"trials":1213,"activeCount":74},[1214],{"nctId":1215,"briefTitle":1216,"status":275,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":449,"enrollment":111,"conditions":1219,"interventions":1221},"NCT02989207","Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans",[67],"2017-12",[1220],"Primary Open Angle Glaucoma",[1200],{"intervention":1223,"totalTrials":70,"cells":1224},"Venetoclax",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1226,"activeCount":74},[],{"trials":1228,"activeCount":74},[],{"trials":1230,"activeCount":74},[],{"trials":1232,"activeCount":74},[],{"trials":1234,"activeCount":74},[],{"trials":1236,"activeCount":74},[1237],{"nctId":1238,"briefTitle":1239,"status":275,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT05312112","Real World Outcomes Using Novel Agents for AML in the UK",[],"2023-10-01","2022-05-01",1000,[1245],"Acute Myeloid Leukemia",[1223,1247],"Gilteritinib",{"intervention":1247,"totalTrials":70,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":74},[],{"trials":1253,"activeCount":74},[],{"trials":1255,"activeCount":74},[],{"trials":1257,"activeCount":74},[],{"trials":1259,"activeCount":74},[],{"trials":1261,"activeCount":74},[1262],{"nctId":1238,"briefTitle":1239,"status":275,"phases":1263,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1264,"interventions":1265},[],[1245],[1223,1247],{"intervention":1267,"totalTrials":70,"cells":1268},"Angiotensin II",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1270,"activeCount":74},[],{"trials":1272,"activeCount":74},[],{"trials":1274,"activeCount":74},[],{"trials":1276,"activeCount":74},[],{"trials":1278,"activeCount":74},[],{"trials":1280,"activeCount":74},[1281],{"nctId":1282,"briefTitle":1283,"status":275,"phases":1284,"primaryCompletion":1285,"completion":890,"start":1286,"enrollment":1113,"conditions":1287,"interventions":1289},"NCT04408326","Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome",[],"2022-07-31","2020-06-01",[1288,918],"COVID",[1267,1290],"Interleukin-1 receptor antagonist",{"intervention":1290,"totalTrials":70,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1294,"activeCount":74},[],{"trials":1296,"activeCount":74},[],{"trials":1298,"activeCount":74},[],{"trials":1300,"activeCount":74},[],{"trials":1302,"activeCount":74},[],{"trials":1304,"activeCount":74},[1305],{"nctId":1282,"briefTitle":1283,"status":275,"phases":1306,"primaryCompletion":1285,"completion":890,"start":1286,"enrollment":1113,"conditions":1307,"interventions":1308},[],[1288,918],[1267,1290],{"intervention":1310,"totalTrials":70,"cells":1311},"AEONTM Repair",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1313,"activeCount":74},[],{"trials":1315,"activeCount":74},[],{"trials":1317,"activeCount":74},[],{"trials":1319,"activeCount":74},[],{"trials":1321,"activeCount":74},[],{"trials":1323,"activeCount":74},[1324],{"nctId":1325,"briefTitle":1326,"status":275,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1335},"NCT04131335","Use of Prophylactic Lubricating Drops After Cataract Surgery",[67],"2020-06","2019-10-14",168,[1174,1332,1333,1334],"Cataract Surgery","Patient Related Outcome Measures","Patient Satisfaction",[1310],{"intervention":1337,"totalTrials":70,"cells":1338},"domperidone or esomeprazole",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1340,"activeCount":74},[],{"trials":1342,"activeCount":74},[],{"trials":1344,"activeCount":74},[],{"trials":1346,"activeCount":74},[],{"trials":1348,"activeCount":74},[],{"trials":1350,"activeCount":74},[1351],{"nctId":1352,"briefTitle":1353,"status":771,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1361},"NCT00604942","vMII for Measurement of Oesophageal Bolus Transport and Reflux",[67],"2010-10","2007-11",140,[1359,1360],"Achalasia","GORD",[1337,1362],"Esomeprazole 40 mg",{"intervention":1362,"totalTrials":70,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1366,"activeCount":74},[],{"trials":1368,"activeCount":74},[],{"trials":1370,"activeCount":74},[],{"trials":1372,"activeCount":74},[],{"trials":1374,"activeCount":74},[],{"trials":1376,"activeCount":74},[1377],{"nctId":1352,"briefTitle":1353,"status":771,"phases":1378,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1357,"conditions":1379,"interventions":1380},[67],[1359,1360],[1337,1362],{"intervention":1382,"totalTrials":70,"cells":1383},"Ropivicaine",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1385,"activeCount":74},[],{"trials":1387,"activeCount":74},[],{"trials":1389,"activeCount":74},[],{"trials":1391,"activeCount":74},[],{"trials":1393,"activeCount":74},[],{"trials":1395,"activeCount":74},[1396],{"nctId":1397,"briefTitle":1398,"status":275,"phases":1399,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1408},"NCT02838329","Labour Epidural Top-up With Warmed Ropivacaine",[67],"2018-12","2016-07",90,[1404,1405,1406,1407],"Epidural Top-up","Labour","Caesarian Section","Ropivacaine",[1382],{"intervention":1410,"totalTrials":70,"cells":1411},"Xenon",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1413,"activeCount":74},[],{"trials":1415,"activeCount":74},[],{"trials":1417,"activeCount":74},[],{"trials":1419,"activeCount":74},[],{"trials":1421,"activeCount":74},[],{"trials":1423,"activeCount":74},[1424],{"nctId":1425,"briefTitle":1426,"status":403,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":566,"enrollment":1430,"conditions":1431,"interventions":1434},"NCT03968861","Outcome After 24 Months of Participants in the TOBY Xenon Study",[],"2017-06","2018-05",69,[1432,1433],"Perinatal Asphyxia","Encephalopathy",[1410]]